Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers analyzed cancer outcomes among a large group of South Koreans with hepatitis B virus.
Immunotherapy did not improve overall survival but led to fewer side effects and better quality of life.
South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.
Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.
In my heart and mind, the real story of Erika Zak is about organ donation awareness. With more people listed, less people die.
A new study appears to resolve controversy over hep C treatment’s association with mortality risk.
Researchers compared health outcomes among people with HIV, including those with and without hepatitis C.
An analysis conducted in Taiwan analyzed health outcomes over more than a decade.
An honest look at what it feels like to live with advanced liver disease.
Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.
Researchers reached this conclusion after reviewing data on more than 30,000 people.
European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Study in China sees an association with several cancer types, especially gastrointestinal malignancies.
Learning to live well with liver disease, even at it’s worst stages, is possible if you know how to.
Analysis of nearly 34,000 people finds no serious adverse events associated with direct-acting antiviral therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.